PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
about
T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced DamageMesothelial cells in tissue repair and fibrosisMesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal DialysisMesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer.Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transitionTamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.Intra-abdominal fat depots represent distinct immunomodulatory microenvironments: a murine model.Transition of mesothelial cell to fibroblast in peritoneal dialysis: EMT, stem cell or bystander?Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damagemiR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.Angiogenesis in peritoneal dialysis.Protective measures against ultrafiltration failure in peritoneal dialysis patientsPharmacologic targets and peritoneal membrane remodeling.Preserving the peritoneal membrane in long-term peritoneal dialysis patients.Is there such a thing as biocompatible peritoneal dialysis fluid?Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition.Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis.Immune-Regulatory Molecule CD69 Controls Peritoneal Fibrosis.Mesothelial-to-mesenchymal transition in the pathogenesis of post-surgical peritoneal adhesions.Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.New insights into therapeutic strategies for the treatment of peritoneal fibrosis: learning from histochemical analyses of animal models.Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process?Activation of peroxisome proliferator-activated receptor-gamma by glitazones reduces the expression and release of monocyte chemoattractant protein-1 in human mesothelial cells.Pathways responsible for apoptosis resulting from amadori-induced oxidative and nitrosative stress in human mesothelial cells.Cloning, structural characterization and expression analysis of a novel lipid storage droplet protein-1 (LSD-1) gene in Chinese honeybee (Apis cerana cerana).Telmisartan attenuates peritoneal fibrosis via peroxisome proliferator-activated receptor-γ activation in rats.Increased peritoneal damage in glyoxalase 1 knock-down mice treated with peritoneal dialysis.RhoA/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis.Exosomal miR-21-5p derived from gastric cancer promotes peritoneal metastasis via mesothelial-to-mesenchymal transition
P2860
Q27002418-0F3FE7CB-3CB0-434E-A61B-00CE866206BEQ28088764-FE46F409-58ED-43F2-978E-85228B477C48Q28390104-23B1548D-3BA8-4285-B627-932D902B33A6Q33788703-B4B5FE8A-481C-4BA0-9E54-69F1D2804512Q34667822-E8D6BB4B-2A7D-4D35-BB02-34E24EEA1441Q34700117-C73E9BA3-B359-4E32-994C-FD5FBC9F01C3Q34776726-CDD15FAE-4C8A-4BFC-B11A-135F0D3CBD95Q35106053-E7B55F06-35D9-46B9-8EEA-FD9328EEB573Q35210203-CCDD574D-B278-4402-B39E-A54000D664B9Q36615791-C85A5058-FD7F-40DB-B9A2-60834F6F7CBCQ37327436-151161F8-EBDC-4430-BD42-C063E0735287Q37892307-8A19B0FC-8E1C-4EFD-8A91-290C250ECD4FQ37970606-2B220789-0702-4B12-BA7C-1945D3984006Q38187841-C94D5946-B173-4DFD-8D10-F1C2D452D131Q38568149-29B5C400-624E-41D2-95FC-F23B4EFAD91AQ38976940-E01D1AFB-D134-4778-BEBC-EC132FE5FA89Q39033979-6AC731A0-2B48-4F1E-BE0F-DD82895BFF0DQ39082233-0C5D5154-99ED-46E8-9E76-7D1ADB15F150Q39789853-A7B9C77B-3372-459B-B9E0-98A9AA462DFFQ39856481-4FE675A4-F4F1-4752-BCC6-3FBF2D6CB5D9Q40258774-71D2D977-5CEC-45A1-8426-2922B0EB6143Q41181702-E4C1029A-2C4F-4386-BFD9-DDBE9F1344D3Q42002311-E032B4B4-986E-4C17-9BE7-2ADD0C8D97BAQ42046471-742B26DB-E0E4-4B90-8EEE-D9BF27A1B8C6Q42141441-7642E38B-27C5-44A1-96BF-4A4EC8BDD343Q45272890-0307AAFC-7911-4929-B04C-2666AD370431Q46204652-CECC12B9-63DB-4FC7-B80E-72AC8E3B3A89Q53544896-72F5F8A6-6921-4B23-8FC4-FF34A442EE76Q54185478-40571947-A2BA-4479-8B70-9DE8DD680C28Q54981633-BDFF6E79-1EFE-4BF3-8654-D111C3FEF006Q58699470-9D322FF0-F224-4627-80C7-5A475AFBEC82
P2860
PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage.
@en
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage.
@nl
type
label
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage.
@en
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage.
@nl
prefLabel
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage.
@en
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage.
@nl
P2093
P2860
P50
P1476
PPAR-γ agonist rosiglitazone p ...... dialysis fluid-induced damage
@en
P2093
Abelardo Aguilera
Alberto Ortiz
Alejandra Maldonado-Rodríguez
Beatriz Santamaría
Jesús Loureiro
José A Sánchez-Tomero
Lorea Mendoza
Rafael Selgas
P2860
P2888
P304
P356
10.1038/LABINVEST.2010.111
P50
P577
2010-06-07T00:00:00Z